prostate cancer

[Journal of Biological Chemistry] Scientists examined for the first time the effect of N-myc-downregulated gene 1 (NDRG1) on androgen receptor expression, activation, and downstream signaling in LNCaP, 22Rv1 and C4-2B prostate cancer cell types.

[Journal of inorganic Biochemistry] Microscopy cellular studies, carried out on the prostate cancer cell line, showed that oxaliplatin inhibited the angiogenin prompting effect on cell proliferation and migration, which were typical features of angiogenesis process.

[Journal of Experimental & Clinical Cancer Research] Researchers indicated that the modulation of NF-YA isoforms affected prostate pathophysiological processes and contributed to a cancer-relevant phenotype, in vitro and in vivo.

[Neoplasia] A major challenge to the treatment of advanced prostate cancer (PCa) is the development of resistance to androgen-deprivation therapy (ADT) and chemotherapy. GH1504 exhibited potent in vitro cytotoxicity in a broad spectrum of human cancer cells, including PCa cells refractory to ADT and chemotherapy.

[Oncogene] The tumor suppressor gene TP53 is the most frequently mutated gene in numerous cancer types, including prostate cancer (PCa). Investigators found that mutant p53 acted in a context-dependent manner to elicit pro-tumorigenic transcriptional profiles.

[Clinical Cancer Research] The authors provide a unique depth and breadth of perspective regarding the diverse immunotherapy strategies currently under clinical investigation for men with advanced prostate cancer.